查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1806547

按產品類型、測試類型、樣本類型、技術、便攜性、購買模式、應用、最終用戶和分銷管道就地檢驗市場 - 全球預測 2025-2030

Point of Care Testing Market by Product, Test Type, Sample Type, Technology, Portability, Mode of Purchase, Application, End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計就地檢驗到 2024 年將達到 328.7 億美元，到 2025 年將達到 371.3 億美元，到 2030 年將達到 691.7 億美元，複合年成長率為 13.19%。

主要市場統計數據
基準年2024年 328.7億美元
預計2025年 371.3億美元
預測年份 2030 691.7億美元
複合年成長率（%） 13.19%

清晰的行業介紹，重點介紹分散診斷、先進檢測和數位融合如何重新定義臨床決策路徑

即時檢測 (POC) 持續重塑診斷技術，使及時的臨床決策更貼近患者。本介紹概述了即時檢測生態系統的現代輪廓，重點介紹了分散式診斷、數位連接和治療決策支援的融合。隨著醫療保健系統優先考慮快速分流、基於價值的護理和門診病人管理，POC 模式因其縮短臨床等待時間和改善患者體驗的能力而日益受到重視。

多重檢測、連結性和護理服務模式的進步如何推動分散診斷實踐的系統變革

在技​​術、醫療服務模式和患者期望的推動下，就地檢驗領域正在經歷一場變革。首先，技術發展軌跡正從單一分析物快速檢測轉向連接複用平台和整合分子工作流程，從而能夠在需要時進行更廣泛的診斷。同時，感測器微型化和微流體整合正在減少樣本量和周轉時間，使家庭和門診檢測更加可行。

評估 2025 年美國關稅對 POC 檢測相關人員的多方面業務和供應鏈影響

2025年美國實施的關稅和貿易措施將對即時檢測 (POC) 領域的製造商、供應商和最終用戶產生複雜影響。對零件、耗材和成品設備徵收的關稅將增加依賴全球供應鏈的產品到岸成本，並可能影響籌資策略和重新訂購時機。由於許多儀器和試劑包含來自多個地區的電子元件、塑膠零件和精密加工零件，因此關稅導致的成本增加可能會因特定子零件的產地而異。

綜合細分分析，整合產品、技術、測試類型、可移植性、購買模式、應用、最終用戶、樣本類型和配銷通路動態，為您的戰略提供資訊

細分洞察揭示了產品類型、檢測類型、樣本基質、技術、便攜性選項、採購模式、應用、最終用戶和分銷管道如何影響需求模式和開發優先順序。在產品細分中，耗材、服務和軟體、儀器和分析儀以及試劑和檢測方法各自具有不同的意義。耗材、配件、服務維護和校準以及軟體和連接性支援持續的收益流和業務連續性；桌上型分析儀、分子平台、可攜式分析儀、讀取器和掃描儀決定了部署場景和臨床工作流程；血糖試紙、血液學試劑、免疫檢測測定試劑、橫向流動化驗試劑和分子檢測試劑套件推動特定檢測的供應鏈紙和品質保證。

美洲、中東和非洲以及亞太地區的地理差異將如何影響 POC 的採購、監管和部署

區域差異顯著影響著即時檢驗 (POC) 檢測的設計、部署和報銷方式，美洲、歐洲、中東和非洲以及亞太地區各自呈現出不同的市場驅動力和營運考量。在美洲，醫療保健系統優先考慮門診病人護理最佳化和慢性病管理，這催生了對支持遠端監控以及在診所和家庭環境中進行快速心血管和代謝檢測的設備和檢測法的需求。該地區的分銷網路優先考慮整合供應鏈和本地化服務支持，青睞那些能夠提供強大售後服務並與主流電子健康記錄數據互通性的製造商。

策略競爭行動和以平台為中心的創新將決定診斷生態系統的準備度、彈性和長期差異化

POC 檢測的競爭格局以策略夥伴關係、平台差異化以及對整合儀器、耗材和軟體的整合解決方案的關注為特徵。主要企業正在優先考慮支援多種檢測格式的模組化平台架構，以實現更快的檢測部署，並提升產品生命週期價值，以應對持續成長的耗材需求。同時，與連接供應商和醫療 IT 整合商合作，對於提供數據豐富的診斷結果，並將其融入臨床工作流程和人口健康舉措，變得至關重要。

企業應採取切實可行的優先策略舉措，以確保診斷方法的採用、供應彈性和持續的商業性差異化

為了保持競爭力並保持臨床相關性，行業領導者應採取一系列切實可行的舉措，使產品開發與業務現實和不斷發展的護理模式保持一致。首先，透過優先考慮互通性和以使用者為中心的軟體設計，實現與臨床醫生工作流程和電子健康記錄的無縫整合，減少部署摩擦。其次，投資模組化平台策略，實現快速的檢測可擴展性並支援多種樣本類型，從而提高採購團隊的靈活性，並減少對多台儀器的需求。

基於主要相關人員訪談、嚴格的二次研究和資料三角測量的透明且可複製的研究途徑，以檢驗

本分析所採用的調查方法結合了定性和定量分析，旨在確保研究的嚴謹性、有效性和可重複性。主要研究包括對臨床醫生、實驗室主任、採購負責人以及設備製造商和經銷商的高級管理人員進行深入訪談，以了解實際使用案例、採購限制和未滿足的需求。這些訪談也輔以機構層級的觀察和對工作流程整合點的檢驗，將臨床優先事項轉化為產品需求。

結論性綜合強調了平衡快速診斷途徑、營運彈性和嚴格品管以實現臨床影響的重要性

總而言之，即時檢測正處於曲折點，技術日趨成熟，醫療服務模式的轉變以及政策的轉變正在共同重新定義診斷路徑。雖然向分散式診斷的轉變得益於檢測化學、小型化設備和軟體連接方面的進步，但這種轉變也帶來了營運、監管和供應鏈方面的挑戰，需要刻意加以緩解。關稅、不斷變化的採購偏好以及區域監管的差異性增加了複雜性，相關人員必須透過靈活的採購、適應性強的產品架構和可靠的證據產生來應對這些挑戰。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 分散的醫療機構和急診對快速且準確的診斷的需求日益增加
  • 透過整合遠端患者監護和虛擬醫療服務的即時檢測來擴展遠端醫療
  • 可攜式多重免疫檢測的普及使得在床邊進行全面的多分析物檢測成為可能
  • 利用快速即時藥敏檢測擴大分散式抗菌藥物抗藥性監測
  • 將一次性微流體盒與可重複使用的分析儀結合可降低測試成本
  • 擴大採用近患者凝血和止血監測進行門診病人抗凝血治療的管理和給藥
  • 雲端基礎的品管和集中分析平台整合，以監控遠端設備性能
  • 擴大急診室的心臟生物標記照護現場檢測可縮短治療時間
  • 投資專為低資源和人道主義部署而設計的堅固耐用的診斷和太陽能 POC 設備
  • 使用可互通的無線連接標準，將 POC 結果即時安全地傳輸到 EHR

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第 8 章就地檢驗市場（按產品）

  • 消費服務和軟體
    • 耗材及配件
    • 服務維護和校準
    • 軟體和連接
  • 測量和分析設備
    • 桌上型分析儀
    • 分子平台
    • 可攜式分析儀
    • 閱讀器和掃描儀
  • 試劑和測定法
    • 血糖試紙
    • 血液學試劑
    • 免疫檢測
    • 橫向流動化驗試劑
    • 分子檢測試劑套件

第9章。就地檢驗市場（依測試類型）

  • 血氣
  • 心臟標記物
    • B型利鈉肽
    • 肌鈣蛋白
  • 綜合代謝組
  • 藥物濫用檢測
  • 血液學
    • 血液凝固檢驗
      • 活化部份凝血活酵素時間
      • 纖維蛋白原水平
      • 凝血酶原時間與國際標準化比
    • 全血球計數
  • 感染疾病
    • 胃腸道傳染病檢查
    • 呼吸道傳染病檢查
    • 性行為感染傳染病檢測
  • 分子診斷
  • 懷孕和不孕症治療
  • 尿液檢查

第 10 章。以樣本類型就地檢驗市場

  • 血
  • 鼻腔和拭子樣本
  • 唾液
  • 尿

第 11 章。就地檢驗市場（按技術）

  • 生物感測器電化學
  • 比色分析平台
  • 免疫檢測
  • 橫向流動化驗
    • 抗體檢測
    • 抗原檢測
    • 多重側流
  • 微流體
  • PCR和分子

第 12就地檢驗市場（依便攜性）

  • 桌上型固定分析儀
  • 可攜式手持設備

第 13 章。以採購方式就地檢驗市場

  • 市售測試套件
  • 處方箋測試

第14章就地檢驗市場（依應用）

  • 慢性病管理
  • 急診及嚴重治療
  • 感染疾病診斷
  • 職業和職場測試
  • 腫瘤監測
  • 女性健康

第 15 章。就地檢驗）

  • 門診治療中心
  • 診斷實驗室
  • 獨立急診科
  • 居家護理
  • 醫院和診所
  • 急診醫療中心

第16章就地檢驗市場（依通路）

  • 離線
    • 直銷
    • 分銷商和批發商
    • 零售和藥局
  • 線上

17. 美國就地檢驗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

18. 歐洲、中東和非洲就地檢驗市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

19. 亞太地區就地檢驗市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第20章 競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • Abaxis, Inc. by Zoetis Inc
    • AccuBioTech Co., Ltd.
    • ACON Laboratories, Inc.
    • Beckman Coulter
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • bioMerieux SA
    • CardioGenics Holdings Inc.
    • Chembio Diagnostic Systems, Inc. by Biosynex
    • Danaher Corporation
    • EKF Diagnostics Holdings
    • GE Healthcare Technologies, Inc.
    • Medtronic Plc
    • Nova Biomedical Corporation
    • OraSure Technologies, Inc.
    • Quidel Corporation
    • Radiometer Medical ApS
    • Randox Laboratories Ltd.
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.

第21章 研究人工智慧

第22章 研究統計

第23章 研究聯絡人

第24章 研究報導

第25章 附錄

Product Code: MRR-035AB9C0DA8B

The Point of Care Testing Market was valued at USD 32.87 billion in 2024 and is projected to grow to USD 37.13 billion in 2025, with a CAGR of 13.19%, reaching USD 69.17 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 32.87 billion
Estimated Year [2025] USD 37.13 billion
Forecast Year [2030] USD 69.17 billion
CAGR (%) 13.19%

A clear industry introduction highlighting how decentralized diagnostics, advanced assays, and digital convergence are redefining clinical decision pathways

Point of care testing continues to reshape diagnostics by bringing timely clinical decision-making closer to the patient. This introduction outlines the contemporary contours of the point of care testing ecosystem, emphasizing the convergence of decentralized diagnostics, digital connectivity, and therapeutic decision support. As health systems prioritize faster triage, value-based care, and outpatient management, point of care modalities are increasingly evaluated for their capacity to reduce clinical latency and improve patient experience.

Advances in miniaturized instrumentation, assay chemistry, and molecular methods now permit a broader range of analytes to be tested outside central laboratories. At the same time, software and connectivity tools are maturing to facilitate result integration with electronic health records and telehealth workflows. These developments are encouraging new use cases within emergency care, chronic disease monitoring, and community screening programs. Consequently, stakeholders across the value chain are recalibrating product development, reimbursement strategies, and distribution models to support rapid adoption while ensuring quality and regulatory compliance.

How converging advances in multiplexed assays, connectivity, and care delivery models are driving systemic change in decentralized diagnostic practice

The landscape of point of care testing is undergoing transformative shifts driven by technology, care delivery models, and patient expectations. First, the technological trajectory is moving from single-analyte rapid tests toward multiplexed platforms and integrated molecular workflows, enabling broader diagnostic breadth at the point of need. Concurrently, sensor miniaturization and microfluidic integration are reducing sample volume and turnaround time, which enhances feasibility for home and ambulatory environments.

Second, care delivery models are evolving: outpatient and community settings are absorbing responsibilities historically held by centralized laboratories, and telemedicine interfaces increasingly rely on near-real-time diagnostics to inform remote consultations. Third, the role of software and connectivity has intensified, with interoperability and cybersecurity becoming prerequisites for clinical adoption. Regulatory pathways are also adapting to accommodate decentralized diagnostics, creating opportunities as well as expectations for robust quality management systems. Finally, patient-centric trends-such as convenience, rapid reassurance, and longitudinal monitoring-are reshaping product design priorities, emphasizing user experience, simplified workflows, and clear result interpretation. Together, these shifts are not incremental but collectively redefine procurement decisions, clinical pathways, and competitive positioning across the ecosystem.

Assessing the multifaceted operational and supply chain consequences of United States tariff measures introduced in 2025 on point of care testing stakeholders

The imposition of tariffs and trade measures by the United States in 2025 introduces a complex set of effects for manufacturers, suppliers, and end users in the point of care testing space. Tariffs on components, consumables, and finished devices can elevate landed costs for products that rely on global supply chains, thereby influencing procurement strategies and reorder cadence. Since many instruments and reagents incorporate electronic components, plastics, and precision machined parts sourced from multiple geographies, tariff-driven cost escalation tends to be uneven and dependent on the origin of specific subcomponents.

In response to tariff pressures, manufacturers may accelerate regional sourcing strategies, increase vertical integration of critical elements, or relocate certain production activities to tariff-favored jurisdictions. These operational adjustments can mitigate exposure but often require near-term capital and redesign efforts. For healthcare providers and distributors, the cumulative effect of tariffs can shift purchasing towards products with more stable supply chain footprints, local assembly, or alternative suppliers offering comparable clinical performance. Pricing adjustments may also influence inventory policies, with stakeholders maintaining higher safety stocks to buffer against potential re-pricing or delays. Importantly, the regulatory and quality assurance implications of sourcing changes necessitate careful validation to ensure clinical equivalence, so organizations must balance cost-containment with the need to preserve test accuracy and continuity of care.

Comprehensive segmentation analysis uniting product, technology, test type, portability, purchase mode, application, end user, sample type, and distribution channel dynamics to inform strategy

Segmentation insights reveal how distinct product categories, test types, sample matrices, technologies, portability options, purchase modes, applications, end users, and distribution channels shape demand patterns and development priorities. Within product segmentation, consumables, services and software, instruments and analyzers, and reagents and assays each carry discrete implications: consumables, accessories and service maintenance and calibration, and software and connectivity underpin ongoing revenue streams and operational continuity; benchtop analyzers, molecular platforms, portable analyzers, and readers and scanners determine deployment scenarios and clinical workflows; while glucose test strips, hematology reagents, immunoassay reagents, lateral flow assay reagents, and molecular assay kits drive assay-specific supply chain and quality assurance requirements.

When viewed through test-type segmentation, the breadth from blood gases to infectious disease and molecular diagnostics affects instrument selection and clinician training, with cardiac markers and hematology requiring specialized assay robustness and coagulation testing demanding precise calibration and control across activated partial thromboplastin time, fibrinogen level, and prothrombin time and international normalized ratio assays. Infectious disease testing spans gastrointestinal, respiratory, and sexually transmitted infection panels, each influencing throughput needs and biosafety considerations. Sample-type segmentation, including blood, nasal and swab samples, saliva, and urine, informs collection device design, patient acceptability, and pre-analytical stability requirements. Technology segmentation differentiates biosensor electrochemical approaches, colorimetric platforms, immunoassays, lateral flow assays-spanning antibody, antigen, and multiplex formats-microfluidics, and PCR and molecular technologies, with each imparting trade-offs between sensitivity, specificity, cost, and operational complexity.

Portability options distinguish benchtop fixed analyzers from portable handheld devices, aligning device footprint with intended point of care settings. Mode of purchase segmentation separates over-the-counter accessibility from prescription-based dispensing, shaping labeling, user instructions, and post-market surveillance obligations. Application-driven segmentation-from chronic disease management to emergency and critical care, infectious disease diagnosis, occupational testing, oncology monitoring, and women's health-dictates performance thresholds and integration requirements with clinical care pathways. End-user segmentation that includes ambulatory care centers, diagnostic laboratories, free-standing emergency departments, home care, hospitals and clinics, and urgent care centers emphasizes differences in staffing, regulatory oversight, and capital acquisition processes. Finally, distribution channel segmentation across offline and online pathways, with offline methods such as direct sales, distributor and wholesale, and retail and pharmacy, impacts go-to-market strategies, margin structures, and customer support models. Taken together, these segmentation lenses provide a multifaceted view that guides product roadmaps, commercialization priorities, and lifecycle planning.

How geographic differences across the Americas, Europe Middle East and Africa, and Asia-Pacific shape procurement, regulation, and deployment of point of care diagnostics

Regional nuances significantly influence how point of care testing is designed, deployed, and reimbursed, with the Americas, Europe, Middle East and Africa, and Asia-Pacific each presenting distinct market drivers and operational considerations. In the Americas, health systems emphasize outpatient care optimization and chronic disease management, creating demand for devices and assays that support remote monitoring and rapid cardiovascular and metabolic testing in both clinic and home settings. Distribution networks in this region prioritize integrated supply chains and localized service support, which favors manufacturers that can demonstrate robust after-sales service and data interoperability with dominant electronic health records.

Europe, Middle East and Africa exhibit heterogeneity in regulatory regimes and healthcare infrastructure, with pockets of high regulatory rigor coexisting with areas where access barriers remain. This diversity requires adaptable product configurations and flexible pricing models. Interoperability standards and data privacy frameworks are especially influential in regulatory decision-making and clinical adoption in Europe, while capacity building and decentralized solutions are prioritized in many parts of the Middle East and Africa. In Asia-Pacific, rapid urbanization, expanding primary care networks, and high-volume public health screening initiatives drive demand for scalable, cost-effective point of care solutions. Regional manufacturing capabilities and supplier ecosystems in Asia-Pacific often accelerate product iteration cycles, and partnerships with local distributors are critical to achieve penetration across varied healthcare settings. Across all regions, reimbursement pathways, regulatory timelines, and customer training imperatives shape adoption velocity and product design choices.

Strategic competitive behaviors and platform-focused innovation that determine preparedness, resilience, and long-term differentiation within the diagnostic ecosystem

Competitive dynamics within the point of care testing landscape are characterized by strategic partnerships, platform differentiation, and a focus on integrated solutions that combine instruments, consumables, and software. Leading companies are prioritizing modular platform architectures that support multiple assay formats, enabling faster assay rollouts and improved lifetime value through recurring consumable demand. Concurrently, alliances with connectivity vendors and health IT integrators are becoming essential to deliver data-rich diagnostic results that plug into clinical workflows and population health initiatives.

Innovation strategies vary by firm, with some investing heavily in molecular and microfluidic technologies to expand the diagnostic menu, while others concentrate on low-cost lateral flow and biosensor technologies optimized for point-of-care ease of use. Service offerings, including field maintenance, calibration, and software updates, are being redefined as a competitive differentiator, and companies that can demonstrate rapid support turnaround and robust quality systems tend to secure larger institutional contracts. Supply chain resilience and localized manufacturing capabilities have also risen in strategic importance, prompting acquisitions and joint ventures to reduce exposure to global logistics disruptions. Finally, commercial models are shifting toward subscription and outcomes-based arrangements in select accounts, aligning vendor incentives with clinical performance and operational uptime.

Practical and prioritized strategic moves that companies should implement to secure adoption, supply resilience, and sustained commercial differentiation in diagnostics

To remain competitive and clinically relevant, industry leaders should pursue a set of actionable initiatives that align product development with operational realities and evolving care models. First, prioritize interoperability and user-centered software design so that devices integrate seamlessly into clinician workflows and electronic health records, thereby reducing friction at the point of adoption. Second, invest in modular platform strategies that allow rapid assay expansion and support multiple sample types, which increases flexibility for procurement teams and reduces the need for multiple device footprints.

Third, strengthen supply chain resilience through strategic regional sourcing, dual sourcing of critical components, and validated local assembly where feasible, which mitigates exposure to trade disruptions and tariff-driven cost pressures. Fourth, enhance post-market service offerings-particularly field maintenance and remote diagnostics-to preserve instrument uptime and protect clinical continuity. Fifth, adopt evidence-generation strategies that emphasize real-world performance, workflow impact, and patient-centric outcomes, thereby supporting payer discussions and clinical adoption. Finally, explore alternative commercial models, such as managed service agreements or outcome-linked contracts, to better align with healthcare purchasers' objectives and to create predictable revenue streams. Executing these actions with clear accountability and staged milestones will help firms convert technical capabilities into durable market advantage.

A transparent and reproducible research approach combining primary stakeholder interviews, rigorous secondary review, and data triangulation to validate conclusions

The research methodology underpinning this analysis integrates qualitative and quantitative approaches designed to ensure rigor, relevance, and reproducibility. Primary research consisted of in-depth interviews with clinicians, laboratory directors, procurement officers, and senior executives across device manufacturers and distributors to capture real-world use cases, procurement constraints, and unmet needs. These interviews were complemented by facility-level observations and validation of workflow integration points to translate clinical priorities into product requirements.

Secondary research included a systematic review of peer-reviewed clinical literature, regulatory guidance documents, industry standards for quality management and interoperability, and technical white papers describing assay and platform performance. Data triangulation techniques were employed to reconcile insights from diverse sources and to validate assumptions about operational behaviors and adoption barriers. The research also applied scenario analysis to assess supply chain risk and regulatory sensitivity, and key findings were stress-tested through expert panels to refine recommendations. Throughout, the methodology emphasized transparency, with audit trails linking conclusions to source materials and interview excerpts, ensuring that stakeholders can trace analytic judgments back to empirical evidence.

A conclusive synthesis emphasizing the balance between rapid diagnostic access, operational resilience, and rigorous quality controls to realize clinical impact

In conclusion, point of care testing is at an inflection point where technological maturity, changing care delivery models, and policy shifts are jointly redefining diagnostic pathways. The move toward decentralized diagnostics is supported by advances in assay chemistry, miniaturized instrumentation, and software connectivity, yet this transition also raises operational, regulatory, and supply chain challenges that require deliberate mitigation. Tariff actions, shifting procurement preferences, and regional regulatory heterogeneity add layers of complexity that stakeholders must address through resilient sourcing, adaptable product architectures, and robust evidence generation.

For manufacturers, the imperative is to deliver clinically rigorous, easy-to-use platforms that integrate seamlessly into workflows while offering sustainable service and supply models. For providers and payers, the focus should be on harnessing point of care capabilities to improve decision latency and patient experience without sacrificing quality controls. By aligning technology investments, commercial models, and implementation frameworks, stakeholders can realize the promise of point of care testing to deliver meaningful improvements in clinical care and operational efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Increasing demand for rapid, accurate diagnostics in decentralized healthcare settings and urgent care
  • 5.2. Expansion of telemedicine integrating POCT for remote patient monitoring and virtual healthcare services
  • 5.3. Proliferation of portable multiplex immunoassays enabling comprehensive multi-analyte panels at bedside
  • 5.4. Growth of decentralized antimicrobial resistance surveillance using rapid point of care susceptibility testing assays
  • 5.5. Emergence of disposable microfluidic cartridges paired with reusable analyzers to drive down per test costs
  • 5.6. Increased adoption of near-patient coagulation and hemostasis monitoring for outpatient anticoagulant management and dosing
  • 5.7. Integration of cloud-based quality control and centralized analytics platforms for remote device performance monitoring
  • 5.8. Scaling of point of care cardiac biomarker testing in emergency departments to reduce door to treatment times
  • 5.9. Investment in ruggedized diagnostics and solar powered POC devices tailored for low-resource and humanitarian deployments
  • 5.10. Adoption of interoperable wireless connectivity standards to enable secure real-time transmission of POC results to EHRs

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Point of Care Testing Market, by Product

  • 8.1. Introduction
  • 8.2. Consumables Services & Software
    • 8.2.1. Consumables & Accessories
    • 8.2.2. Service Maintenance & Calibration
    • 8.2.3. Software & Connectivity
  • 8.3. Instruments & Analyzers
    • 8.3.1. Benchtop Analyzers
    • 8.3.2. Molecular Platforms
    • 8.3.3. Portable Analyzers
    • 8.3.4. Readers & Scanners
  • 8.4. Reagents & Assays
    • 8.4.1. Glucose Test Strips
    • 8.4.2. Hematology Reagents
    • 8.4.3. Immunoassay Reagents
    • 8.4.4. Lateral Flow Assay Reagents
    • 8.4.5. Molecular Assay Kits

9. Point of Care Testing Market, by Test Type

  • 9.1. Introduction
  • 9.2. Blood Gases
  • 9.3. Cardiac Markers
    • 9.3.1. B-type Natriuretic Peptide
    • 9.3.2. Troponin
  • 9.4. Comprehensive Metabolic Panel
  • 9.5. Drug Of Abuse Testing
  • 9.6. Hematology
    • 9.6.1. Coagulation Tests
      • 9.6.1.1. Activated Partial Thromboplastin Time
      • 9.6.1.2. Fibrinogen Level
      • 9.6.1.3. Prothrombin Time & International Normalized Ratio
    • 9.6.2. Complete Blood Count
  • 9.7. Infectious Disease
    • 9.7.1. Gastrointestinal Infection Tests
    • 9.7.2. Respiratory Infection Tests
    • 9.7.3. Sexually Transmitted Infection Tests
  • 9.8. Molecular Diagnostics
  • 9.9. Pregnancy & Fertility
  • 9.10. Urinalysis

10. Point of Care Testing Market, by Sample Type

  • 10.1. Introduction
  • 10.2. Blood
  • 10.3. Nasal & Swab Samples
  • 10.4. Saliva
  • 10.5. Urine

11. Point of Care Testing Market, by Technology

  • 11.1. Introduction
  • 11.2. Biosensor Electrochemical
  • 11.3. Colorimetric Platforms
  • 11.4. Immunoassay
  • 11.5. Lateral Flow Assays
    • 11.5.1. Antibody Tests
    • 11.5.2. Antigen Tests
    • 11.5.3. Multiplex Lateral Flow
  • 11.6. Microfluidics
  • 11.7. PCR And Molecular

12. Point of Care Testing Market, by Portability

  • 12.1. Introduction
  • 12.2. Benchtop Fixed Analyzers
  • 12.3. Portable Handheld Devices

13. Point of Care Testing Market, by Mode of Purchase

  • 13.1. Introduction
  • 13.2. Over-The-Counter Tests
  • 13.3. Prescription-Based Tests

14. Point of Care Testing Market, by Application

  • 14.1. Introduction
  • 14.2. Chronic Disease Management
  • 14.3. Emergency And Critical Care
  • 14.4. Infectious Disease Diagnosis
  • 14.5. Occupational And Workplace Testing
  • 14.6. Oncology Monitoring
  • 14.7. Women Health

15. Point of Care Testing Market, by End User

  • 15.1. Introduction
  • 15.2. Ambulatory Care Centers
  • 15.3. Diagnostic Laboratories
  • 15.4. Free-Standing Emergency Departments
  • 15.5. Home Care
  • 15.6. Hospitals & Clinics
  • 15.7. Urgent Care Centers

16. Point of Care Testing Market, by Distribution Channel

  • 16.1. Introduction
  • 16.2. Offline
    • 16.2.1. Direct Sales
    • 16.2.2. Distributor & Wholesale
    • 16.2.3. Retail & Pharmacy
  • 16.3. Online

17. Americas Point of Care Testing Market

  • 17.1. Introduction
  • 17.2. United States
  • 17.3. Canada
  • 17.4. Mexico
  • 17.5. Brazil
  • 17.6. Argentina

18. Europe, Middle East & Africa Point of Care Testing Market

  • 18.1. Introduction
  • 18.2. United Kingdom
  • 18.3. Germany
  • 18.4. France
  • 18.5. Russia
  • 18.6. Italy
  • 18.7. Spain
  • 18.8. United Arab Emirates
  • 18.9. Saudi Arabia
  • 18.10. South Africa
  • 18.11. Denmark
  • 18.12. Netherlands
  • 18.13. Qatar
  • 18.14. Finland
  • 18.15. Sweden
  • 18.16. Nigeria
  • 18.17. Egypt
  • 18.18. Turkey
  • 18.19. Israel
  • 18.20. Norway
  • 18.21. Poland
  • 18.22. Switzerland

19. Asia-Pacific Point of Care Testing Market

  • 19.1. Introduction
  • 19.2. China
  • 19.3. India
  • 19.4. Japan
  • 19.5. Australia
  • 19.6. South Korea
  • 19.7. Indonesia
  • 19.8. Thailand
  • 19.9. Philippines
  • 19.10. Malaysia
  • 19.11. Singapore
  • 19.12. Vietnam
  • 19.13. Taiwan

20. Competitive Landscape

  • 20.1. Market Share Analysis, 2024
  • 20.2. FPNV Positioning Matrix, 2024
  • 20.3. Competitive Analysis
    • 20.3.1. F. Hoffmann-La Roche Ltd
    • 20.3.2. Abbott Laboratories
    • 20.3.3. Abaxis, Inc. by Zoetis Inc
    • 20.3.4. AccuBioTech Co., Ltd.
    • 20.3.5. ACON Laboratories, Inc.
    • 20.3.6. Beckman Coulter
    • 20.3.7. Becton, Dickinson and Company
    • 20.3.8. Bio-Rad Laboratories, Inc.
    • 20.3.9. bioMerieux SA
    • 20.3.10. CardioGenics Holdings Inc.
    • 20.3.11. Chembio Diagnostic Systems, Inc. by Biosynex
    • 20.3.12. Danaher Corporation
    • 20.3.13. EKF Diagnostics Holdings
    • 20.3.14. GE Healthcare Technologies, Inc.
    • 20.3.15. Medtronic Plc
    • 20.3.16. Nova Biomedical Corporation
    • 20.3.17. OraSure Technologies, Inc.
    • 20.3.18. Quidel Corporation
    • 20.3.19. Radiometer Medical ApS
    • 20.3.20. Randox Laboratories Ltd.
    • 20.3.21. Siemens Healthineers AG
    • 20.3.22. Thermo Fisher Scientific Inc.

21. ResearchAI

22. ResearchStatistics

23. ResearchContacts

24. ResearchArticles

25. Appendix

LIST OF FIGURES

  • FIGURE 1. POINT OF CARE TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL POINT OF CARE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 18. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 20. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 22. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 26. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 29. ASIA-PACIFIC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 30. ASIA-PACIFIC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 31. POINT OF CARE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. POINT OF CARE TESTING MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 33. POINT OF CARE TESTING MARKET: RESEARCHAI
  • FIGURE 34. POINT OF CARE TESTING MARKET: RESEARCHSTATISTICS
  • FIGURE 35. POINT OF CARE TESTING MARKET: RESEARCHCONTACTS
  • FIGURE 36. POINT OF CARE TESTING MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. POINT OF CARE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL POINT OF CARE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL POINT OF CARE TESTING MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SERVICE MAINTENANCE & CALIBRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SERVICE MAINTENANCE & CALIBRATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SOFTWARE & CONNECTIVITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SOFTWARE & CONNECTIVITY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR PLATFORMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY READERS & SCANNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY READERS & SCANNERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GLUCOSE TEST STRIPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GLUCOSE TEST STRIPS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY REAGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY REAGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR ASSAY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR ASSAY KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD GASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD GASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPREHENSIVE METABOLIC PANEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPREHENSIVE METABOLIC PANEL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DRUG OF ABUSE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DRUG OF ABUSE TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ACTIVATED PARTIAL THROMBOPLASTIN TIME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ACTIVATED PARTIAL THROMBOPLASTIN TIME, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FIBRINOGEN LEVEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FIBRINOGEN LEVEL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PROTHROMBIN TIME & INTERNATIONAL NORMALIZED RATIO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PROTHROMBIN TIME & INTERNATIONAL NORMALIZED RATIO, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPLETE BLOOD COUNT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPLETE BLOOD COUNT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GASTROINTESTINAL INFECTION TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GASTROINTESTINAL INFECTION TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RESPIRATORY INFECTION TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RESPIRATORY INFECTION TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PREGNANCY & FERTILITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PREGNANCY & FERTILITY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINALYSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY NASAL & SWAB SAMPLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY NASAL & SWAB SAMPLES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SALIVA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR ELECTROCHEMICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR ELECTROCHEMICAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COLORIMETRIC PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COLORIMETRIC PLATFORMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIBODY TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIBODY TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIGEN TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIGEN TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MULTIPLEX LATERAL FLOW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MULTIPLEX LATERAL FLOW, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PCR AND MOLECULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PCR AND MOLECULAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP FIXED ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP FIXED ANALYZERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 131. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE HANDHELD DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE HANDHELD DEVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 133. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2025-2030 (USD MILLION)
  • TABLE 135. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OVER-THE-COUNTER TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OVER-THE-COUNTER TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 137. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRESCRIPTION-BASED TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRESCRIPTION-BASED TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 139. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 141. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CHRONIC DISEASE MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CHRONIC DISEASE MANAGEMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 143. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY AND CRITICAL CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY AND CRITICAL CARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 145. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 147. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OCCUPATIONAL AND WORKPLACE TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OCCUPATIONAL AND WORKPLACE TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 149. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONCOLOGY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONCOLOGY MONITORING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 151. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY WOMEN HEALTH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY WOMEN HEALTH, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 153. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 155. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 157. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 159. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FREE-STANDING EMERGENCY DEPARTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FREE-STANDING EMERGENCY DEPARTMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 161. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 163. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 165. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URGENT CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URGENT CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 167. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 169. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 171. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 173. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTOR & WHOLESALE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTOR & WHOLESALE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 175. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RETAIL & PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RETAIL & PHARMACY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 177. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 179. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 181. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 183. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2025-2030 (USD MILLION)
  • TABLE 185. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2025-2030 (USD MILLION)
  • TABLE 187. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 189. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 191. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2025-2030 (USD MILLION)
  • TABLE 193. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
  • TABLE 195. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2025-2030 (USD MILLION)
  • TABLE 197. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 199. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 201. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 203. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 205. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2025-2030 (USD MILLION)
  • TABLE 207. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2025-2030 (USD MILLION)
  • TABLE 209. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 211. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 213. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 215. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 217. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 219. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 221. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 222. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2025-2030 (USD MILLION)
  • TABLE 223. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2024 (USD MILLION)
  • TABLE 224. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2025-2030 (USD MILLION)
  • TABLE 225. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 226. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 227. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 229. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 230. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2025-2030 (USD MILLION)
  • TABLE 231. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 232. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
  • TABLE 233. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 234. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2025-2030 (USD MILLION)
  • TABLE 235. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 236. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 237. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 241. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 242. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 243. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2024 (USD MILLION)
  • TABLE 244. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2025-2030 (USD MILLION)
  • TABLE 245. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2025-2030 (USD MILLION)
  • TABLE 247. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 249. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 251. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 253. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 255. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 257. CANADA POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 258. CANADA POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 259. CANADA POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 260. CANADA POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2025-2030 (USD MILLION)
  • TABLE 261. CANADA POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2024 (USD MILLION)
  • TABLE 262. CANADA POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2025-2030 (USD MILLION)
  • TABLE 263. CANADA POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 264. CANADA POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 265. CANADA POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. CANADA POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 267. CANADA POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 268. CANADA POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2025-2030 (USD MILLION)
  • TABLE 269. CANADA POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. CANADA POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
  • TABLE 271. CANADA POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 272. CANADA POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2025-2030 (USD MILLION)
  • TABLE 273. CANADA POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 274. CANADA POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 275. CANADA POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. CANADA POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 277. CANADA POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. CANADA POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 279. CANADA POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 280. CANADA POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 281. CANADA POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2024 (USD MILLION)
  • TABLE 282. CANADA POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2025-2030 (USD MILLION)
  • TABLE 283. CANADA POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2024 (USD MILLION)
  • TABLE 284. CANADA POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2025-2030 (USD MILLION)
  • TABLE 285. CANADA POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. CANADA POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 287. CANADA POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. CANADA POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 289. CANADA POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. CANADA POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 291. CANADA POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 292. CANADA POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 293. MEXICO POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 294. MEXICO POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 295. MEXICO POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 296. MEXICO POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2025-2030 (USD MILLION)
  • TABLE 297. MEXICO POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2024 (USD MILLION)
  • TABLE 298. MEXICO POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2025-2030 (USD MILLION)
  • TABLE 299. MEXICO POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 300. MEXICO POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2025-2030 (USD MILLION)
  • TABLE 301. MEXICO POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. MEXICO POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 303. MEXICO POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2024 (USD MILLION)
  • TABLE 304. MEXICO POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2025-2030 (USD MILLION)
  • TABLE 305. MEXICO POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. MEXICO POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
  • TABLE 307. MEXICO POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 308. MEXICO POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2025-2030 (USD MILLION)
  • TABLE 309. MEXICO POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 310. MEXICO POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
  • TABLE 311. MEXICO POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. MEXICO POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
  • TABLE 313. MEXICO POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 314. MEXICO POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 315. MEXICO POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
  • TABLE 316. ME